SBI Sourcebio International Plc

TIDMSBI

SourceBio International PLC

22 October 2021

22 October 2021

SourceBio International plc

("SourceBio", the "Company" or "the Group")

Which? endorsement for day two travel PCR test

SourceBio International plc (AIM: SBI), a leading international provider of integrated state-of-the-art laboratory services and products , notes an online article published by Which? titled 'The best cheap day two Covid tests for travel' that recommends SourceBio as the best provider of day two travel COVID-19 PCR testing among a cohort of 50 companies supplying home testing kits, found on www.Gov.uk.

Which? is a non-for-profit organisation which provides impartial expert advice and recommendations to help consumers make better decisions. During the review, Which? applied various criteria to narrow the list of 50 companies down to 7 to investigate with a mystery shopper, a common practice used by retailers, market research and consumer watchdogs to measure the quality of customer service . Which? then shopped at each supplier 13 times to check how often the test kits and results arrived on time.

The mystery shop concluded that SourceBio's travel COVID-19 PCR test was the most reliable of all providers, with test kits and results arriving on time on 12 out of 13 occasions. The endorsement from Which? is a significant achievement given the complete impartiality of the selection process and underlines the excellent customer service and affordability of the day two PCR testing service offering by the Group.

Jay LeCoque, Executive Chairman, commented : "We are delighted to be named by Which? as the best provider of affordable day two consumer travel PCR testing. Which? is a completely impartial organisation and their review process involved a comprehensive mystery shop process, highlighting SourceBio's PCR testing service as the most reliable out of 50 businesses assessed. Outstanding customer service has always been central to SourceBio, and we will continue to maintain this standard as our customers trust us with their day two travel PCR testing."

For further information please contact:

 
 SourceBio International plc                     www.sourcebiointernational.com 
 Jay LeCoque, Executive Chairman                                Via Walbrook PR 
 Tony Ratcliffe, Chief Financial 
  Officer 
 
 
 
 
 Walbrook PR Limited             Tel: 020 7933 8780 or sourcebio@walbrookpr.com 
 Paul McManus / Sam Allen                    Mob: 07980 541 893 / 07502 558 258 
 
 

About SourceBio International plc www.sourcebiointernational.com

SourceBio is a leading international provider of integrated state-of-the-art laboratory services and products with clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four core businesses areas:

-- Infectious Disease Testing - a range of COVID-19 testing services for commercial enterprises, private healthcare groups, NHS and the DHSC. Utilising multiple technologies, including lateral flow testing solutions, SourceBio offers screening, gold standard RT-PCR and whole genome sequencing COVID-19 testing solutions and operates under ISO 15189 accreditation required by the DHSC. SourceBio also provides employee testing solutions to industry, and direct to consumer home test kits (including "Fit to Fly", "Test to Release" and "2 & 8 Day International Travel" approved tests).

-- Healthcare Diagnostics - histopathology cancer screening and clinical diagnostic services for the NHS and private healthcare across the UK and Ireland.

-- Genomics - DNA sequencing services for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America.

-- Stability Storage - shelf-life testing services and equipment for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA.

More details on Group operations can be found here: www.sourcebioscience.com .

SourceBio International plc (SBI) is listed on the AIM market of the London Stock Exchange.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFLFVEIDLLFIL

(END) Dow Jones Newswires

October 22, 2021 02:00 ET (06:00 GMT)

Sourcebio (LSE:SBI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Sourcebio (LSE:SBI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024